Skip to content

Potassium handling in chronic hemodialysis patients in response to higher dialysate potassium

Potassium handling in chronic hemodialysis patients in response to higher dialysate potassium

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23110
Enrollment
24
Registered
2019-03-20
Start date
2019-03-20
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, End-Stage Renal Disease

Interventions

Hemodialysis patients will be treated using widely used dialysate solutions as part of standard care containing potassium either 2 mmol/L or 4 mmol/L in random order.

Sponsors

AUMC - AMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Adult (age = 18 years) stable anuric hemodialysis patients that undergo treatment 3 x 4 hrs/week. • Written informed consent

Exclusion criteria

Exclusion criteria: • Pre-dialysis serum potassium 6.0 mmol/L or use of potassium binders • Patients with previous history of ventricular cardiac arrhythmia • Uncontrolled hypertension (systolic BP >180 mmHg on at least 3 of the last 5 dialysis treatments) or intradialytic hypotension on >3 dialysis treatments in the last month • Patients with insulin dependent diabetes mellitus • Patients with a life expectancy < 6 months • Expected kidney transplantation < 2 months • Cognitively impaired or incapacitated subjects. • Women who are pregnant, breastfeeding or consider pregnancy in the coming 6 months.

Design outcomes

Primary

MeasureTime frame
The primary outcome will be RBC potassium.

Secondary

MeasureTime frame
Secondary endpoints will include serum potassium, potassium removal, serum sodium, sodium removal, total ultrafiltration volume, total body water, and systolic blood pressure as well as changes in serum bicarbonate, insulin, and plasma aldosterone.

Contacts

Public ContactRosa Wouda

AUMC

r.d.wouda@amc.uva.nl0205666136

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)